NASDAQ:APEN Apollo Endosurgery - APEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Apollo Endosurgery, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.83 -0.02 (-0.20%) (As of 01/27/2023 08:54 PM ET) Add Compare Share Share Today's Range$9.82▼$9.8550-Day Range$5.91▼$10.1452-Week Range$3.49▼$10.30Volume802,000 shsAverage Volume1.26 million shsMarket Capitalization$467.42 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Apollo Endosurgery MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside6.8% Upside$10.50 Price TargetShort InterestHealthy1.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.50 out of 5 starsMedical Sector951st out of 1,049 stocksSurgical & Medical Instruments Industry99th out of 105 stocks 1.0 Analyst's Opinion Consensus RatingApollo Endosurgery has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Apollo Endosurgery has a forecasted upside of 6.8% from its current price of $9.83.Amount of Analyst CoverageApollo Endosurgery has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.03% of the outstanding shares of Apollo Endosurgery have been sold short.Short Interest Ratio / Days to CoverApollo Endosurgery has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollo Endosurgery has recently decreased by 10.95%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldApollo Endosurgery does not currently pay a dividend.Dividend GrowthApollo Endosurgery does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APEN. Previous Next 1.8 News and Social Media Coverage News SentimentApollo Endosurgery has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Apollo Endosurgery this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for APEN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apollo Endosurgery insiders have not sold or bought any company stock.Percentage Held by Insiders17.30% of the stock of Apollo Endosurgery is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.01% of the stock of Apollo Endosurgery is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apollo Endosurgery are expected to grow in the coming year, from ($0.97) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apollo Endosurgery is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apollo Endosurgery is -9.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApollo Endosurgery has a P/B Ratio of 6.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Apollo Endosurgery (NASDAQ:APEN) StockApollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.Read More Receive APEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter. Email Address APEN Stock News HeadlinesJanuary 25, 2023 | americanbankingnews.comCowen Downgrades Apollo Endosurgery (NASDAQ:APEN) to Market PerformJanuary 11, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Apollo Endosurgery, Inc. (APEN)January 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 15, 2022 | apnews.comSTOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SAL, VVNT, APEN, GRAYDecember 13, 2022 | finance.yahoo.comApollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with ObesityDecember 8, 2022 | msn.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 TodayDecember 5, 2022 | wsj.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Apollo Endosurgery, Inc. - APENNovember 30, 2022 | bizjournals.comBoston Scientific shells out $615M for gastro device firmJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 29, 2022 | nasdaq.comBoston Scientific to buy Apollo Endosurgery for $417 millionNovember 29, 2022 | reuters.comBoston Scientific to acquire Apollo Endosurgery in $615 mln dealNovember 29, 2022 | finance.yahoo.comApollo Endosurgery to be Acquired by Boston ScientificNovember 29, 2022 | finance.yahoo.comBoston Scientific to acquire Apollo Endosurgery for $615 million in cashNovember 21, 2022 | finance.yahoo.comApollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.November 8, 2022 | finance.yahoo.comApollo Endosurgery, Inc. (NASDAQ:APEN) is largely controlled by institutional shareholders who own 58% of the companyNovember 7, 2022 | finance.yahoo.comApollo Endosurgery to Participate in Upcoming Investor ConferencesNovember 1, 2022 | finance.yahoo.comApollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022October 18, 2022 | finance.yahoo.comApollo Endosurgery to Report Third Quarter Results on November 1, 2022October 12, 2022 | nasdaq.comInvestors in Apollo Endosurgery (NASDAQ:APEN) have made a favorable return of 92% over the past three yearsOctober 10, 2022 | msn.comShort Volatility Alert: Apollo Endosurgery, Inc.September 26, 2022 | finance.yahoo.comApollo Endosurgery, Inc. (APEN)September 17, 2022 | investing.comApollo Tyres Ltd (APLO)September 6, 2022 | finance.yahoo.comMIMEDX Announces Leadership TransitionAugust 31, 2022 | finance.yahoo.comEndoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in MiamiAugust 25, 2022 | finance.yahoo.comApollo Endosurgery, Inc. (NASDAQ:APEN) insider upped their holding by 160% earlier this yearAugust 4, 2022 | finance.yahoo.comApollo Endosurgery (NASDAQ:APEN) hikes 14% this week, taking three-year gains to 156%August 4, 2022 | seekingalpha.comApollo Endosurgery: Collect Shares At A Discount Following Q2 EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter. Email Address APEN Company Calendar Last Earnings11/01/2022Today1/30/2023Next Earnings (Estimated)2/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APEN CUSIPN/A CIK1251769 Webwww.apolloendo.com Phone(512) 279-5100Fax858-678-0900Employees202Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+6.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,680,000.00 Net Margins-56.74% Pretax Margin-56.26% Return on Equity-78.73% Return on Assets-32.99% Debt Debt-to-Equity Ratio1.26 Current Ratio6.00 Quick Ratio4.98 Sales & Book Value Annual Sales$62.99 million Price / Sales7.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book6.34Miscellaneous Outstanding Shares47,550,000Free Float39,323,000Market Cap$467.42 million OptionableNot Optionable Beta2.35 Key ExecutivesCharles S. McKhannPresident, Chief Executive Officer & DirectorJohn MolesphiniExecutive Vice President-OperationsJeffrey G. BlackChief Financial Officer, Secretary & TreasurerChristopher J. GostoutChief Medical OfficerTiffanie GilbrethVice President-Clinical & Medical AffairsKey CompetitorsAnika TherapeuticsNASDAQ:ANIKIRadimedNASDAQ:IRMDLiquidiaNASDAQ:LQDAInovio PharmaceuticalsNASDAQ:INOAngioDynamicsNASDAQ:ANGOView All CompetitorsInsiders & InstitutionsMorris Financial Concepts Inc.Bought 11,149 shares on 1/19/2023Ownership: 0.023%Vanguard Group Inc.Bought 15,400 shares on 11/15/2022Ownership: 3.271%Parkman Healthcare Partners LLCBought 7,690 shares on 11/15/2022Ownership: 1.580%Essex Investment Management Co. LLCBought 11,159 shares on 11/15/2022Ownership: 0.962%Citadel Advisors LLCBought 15,100 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions APEN Stock - Frequently Asked Questions Should I buy or sell Apollo Endosurgery stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" APEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APEN, but not buy additional shares or sell existing shares. View APEN analyst ratings or view top-rated stocks. What is Apollo Endosurgery's stock price forecast for 2023? 3 analysts have issued 12 month target prices for Apollo Endosurgery's shares. Their APEN share price forecasts range from $10.00 to $12.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View analysts price targets for APEN or view top-rated stocks among Wall Street analysts. How have APEN shares performed in 2023? Apollo Endosurgery's stock was trading at $9.97 at the start of the year. Since then, APEN shares have decreased by 1.4% and is now trading at $9.83. View the best growth stocks for 2023 here. Are investors shorting Apollo Endosurgery? Apollo Endosurgery saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 490,600 shares, a decrease of 10.9% from the December 31st total of 550,900 shares. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is presently 0.5 days. View Apollo Endosurgery's Short Interest. When is Apollo Endosurgery's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023. View our APEN earnings forecast. How were Apollo Endosurgery's earnings last quarter? Apollo Endosurgery, Inc. (NASDAQ:APEN) posted its quarterly earnings results on Tuesday, November, 1st. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.07. The biotechnology company had revenue of $19.57 million for the quarter, compared to the consensus estimate of $17.97 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 78.73% and a negative net margin of 56.74%. What guidance has Apollo Endosurgery issued on next quarter's earnings? Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75.00 million-$76.00 million, compared to the consensus revenue estimate of $73.95 million. What other stocks do shareholders of Apollo Endosurgery own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES). What is Apollo Endosurgery's stock symbol? Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN." Who are Apollo Endosurgery's major shareholders? Apollo Endosurgery's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morris Financial Concepts Inc. (0.02%). Insiders that own company stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr. View institutional ownership trends. How do I buy shares of Apollo Endosurgery? Shares of APEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Apollo Endosurgery's stock price today? One share of APEN stock can currently be purchased for approximately $9.83. How much money does Apollo Endosurgery make? Apollo Endosurgery (NASDAQ:APEN) has a market capitalization of $467.42 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24,680,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How many employees does Apollo Endosurgery have? The company employs 202 workers across the globe. How can I contact Apollo Endosurgery? Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The official website for the company is www.apolloendo.com. The biotechnology company can be reached via phone at (512) 279-5100, via email at investor-relations@apolloendo.com, or via fax at 858-678-0900. This page (NASDAQ:APEN) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.